Navigation Links
Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Date:2/12/2008

199,407 40,665 240,072

Generic OTFC 129,033 - 129,033

FENTORA 135,136 - 135,136

AMRIX 8,401 - 8,401

Pain 471,977 40,665 512,642

Other 69,263 236,037 305,300

$1,393,521 $333,778 $1,727,299

Year Ended

December 31,

2006

United

States Europe Total

Sales:

PROVIGIL $684,885 $43,052 $727,937

GABITRIL 54,096 4,316 58,412

CNS 738,981 47,368 786,349

ACTIQ 544,886 27,252 572,138

Generic OTFC 54,801 - 54,801

FENTORA 29,250 - 29,250

AMRIX - - -

Pain 628,937 27,252 656,189

Other 56,084 208,277 264,361

$1,424,002 $282,897 $1,706,899

%

Increase

(Decrease)

United

States Europe Total

Sales:

PROVIGIL 17% 17% 17%

GABITRIL (6%) 54% (2%)


'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email: